Displaying 321 - 340 of 4735
FTC, HHS Seek Public Comment on Generic Drug Shortages and Competition Amongst Powerful Middlemen
FTC to Host Virtual Workshop on Private Equity in Health Care
FTC Submits Comment on March-In Rights to Promote Efforts to Lower Drug Prices
IQVIA Holdings/Propel Media, In the Matter of
On July 17, 2023, the Federal Trade Commission sued to block IQVIA Holdings Inc. (IQVIA) from acquiring Propel Media, Inc. (PMI), alleging in an administrative complaint that the proposed acquisition would give IQVIA a market- leading position in programmatic advertising for health care products, namely prescription drugs, to doctors and other health care professionals. The Commission also authorized FTC staff to seek a temporary restraining order and preliminary injunction in federal district court to prevent IQVIA from consummating its acquisition of PMI, pending the agency’s administrative proceeding.
After a nearly two-week evidentiary hearing and closing arguments in late November and December 2023, U.S. District Court Judge Edgardo Ramos issued an order granting the FTC’s motion for preliminary injunction on December 29, 2023.
Statement Regarding the Termination of Amazon’s Proposed Acquisition of iRobot
CoStar Group v. Commercial Real Estate Exchange
FTC and DOJ Update Guidance That Reinforces Parties’ Preservation Obligations for Collaboration Tools and Ephemeral Messaging
FTC Sues to Block Novant Health’s Acquisition of Two Hospitals from Community Health Systems
FTC Launches Inquiry into Generative AI Investments and Partnerships
Statement on Second Circuit Order Upholding “Pharma Bro” Martin Shkreli’s Lifetime Ban
Federal Trade Commission and Justice Department Hold Trilateral Meeting with Competition Enforcers from Mexico and Canada
Vyera Pharmaceuticals, LLC
The Federal Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote banned Shkreli for life from the pharmaceutical industry.
On January 23, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s ruling.
FTC Announces 2024 Update of Size of Transaction Thresholds for Premerger Notification Filings
FTC Announces 2024 Jurisdictional Threshold Updates for Interlocking Directorates
Syngenta and Corteva, FTC v.
The Federal Trade Commission and state partners have filed a complaint in federal court alleging that pesticide manufacturers Syngenta Crop Protection and Corteva, Inc. have used so-called “loyalty” programs to block and restrict generic competition from pesticide markets, leaving farmers to pay elevated prices for crop protection. The complaint seeks to bar Syngenta and Corteva from continuing these programs and from entering into any similar arrangements in the future, and to restore competition to affected markets.
Displaying 321 - 340 of 4735